IDEAYA Biosciences (IDYA) Competitors $24.05 -0.70 (-2.83%) Closing price 04:00 PM EasternExtended Trading$24.05 0.00 (0.00%) As of 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IDYA vs. ROIV, GRFS, LEGN, RVMD, RYTM, RNA, NUVL, ABVX, AXSM, and CRSPShould you be buying IDEAYA Biosciences stock or one of its competitors? The main competitors of IDEAYA Biosciences include Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Nuvalent (NUVL), Abivax (ABVX), Axsome Therapeutics (AXSM), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. IDEAYA Biosciences vs. Its Competitors Roivant Sciences Grifols Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Avidity Biosciences Nuvalent Abivax Axsome Therapeutics CRISPR Therapeutics IDEAYA Biosciences (NASDAQ:IDYA) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability. Which has more volatility & risk, IDYA or ROIV? IDEAYA Biosciences has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Does the media prefer IDYA or ROIV? In the previous week, Roivant Sciences had 5 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 8 mentions for Roivant Sciences and 3 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.98 beat Roivant Sciences' score of 0.61 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate IDYA or ROIV? IDEAYA Biosciences currently has a consensus price target of $48.09, suggesting a potential upside of 99.96%. Roivant Sciences has a consensus price target of $16.50, suggesting a potential upside of 40.31%. Given IDEAYA Biosciences' higher possible upside, analysts plainly believe IDEAYA Biosciences is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IDEAYA Biosciences 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.77Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.25 Do institutionals & insiders believe in IDYA or ROIV? 98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 2.5% of IDEAYA Biosciences shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is IDYA or ROIV more profitable? IDEAYA Biosciences has a net margin of 0.00% compared to Roivant Sciences' net margin of -2,111.79%. Roivant Sciences' return on equity of -15.90% beat IDEAYA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets IDEAYA BiosciencesN/A -31.42% -29.45% Roivant Sciences -2,111.79%-15.90%-14.95% Which has stronger valuation and earnings, IDYA or ROIV? Roivant Sciences has higher revenue and earnings than IDEAYA Biosciences. Roivant Sciences is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIDEAYA Biosciences$7M301.11-$274.48M-$3.79-6.35Roivant Sciences$29.05M275.20-$171.98M-$0.70-16.80 SummaryRoivant Sciences beats IDEAYA Biosciences on 10 of the 17 factors compared between the two stocks. Get IDEAYA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IDYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IDYA vs. The Competition Export to ExcelMetricIDEAYA BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.11B$3.07B$5.76B$9.64BDividend YieldN/A2.22%3.91%4.09%P/E Ratio-6.3520.4530.7725.11Price / Sales301.11353.46456.03116.28Price / CashN/A41.5625.2228.45Price / Book1.969.559.385.96Net Income-$274.48M-$54.74M$3.26B$265.37M7 Day Performance1.95%2.43%1.90%0.97%1 Month Performance11.39%4.64%3.76%2.49%1 Year Performance-38.43%9.18%28.98%20.23% IDEAYA Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IDYAIDEAYA Biosciences4.4713 of 5 stars$24.05-2.8%$48.09+100.0%-34.5%$2.11B$7M-6.3580ROIVRoivant Sciences2.9881 of 5 stars$11.17-2.8%$16.50+47.7%+5.5%$7.81B$29.05M-44.68860News CoverageGap DownGRFSGrifols3.7988 of 5 stars$10.60-0.6%$10.30-2.8%+49.9%$7.33B$7.81B9.0623,822Short Interest ↑LEGNLegend Biotech3.7264 of 5 stars$36.24-2.1%$73.33+102.4%-34.2%$6.80B$627.24M-61.422,609News CoverageRVMDRevolution Medicines4.1713 of 5 stars$34.70-0.9%$68.82+98.3%-14.9%$6.54B$11.58M-7.71250News CoverageAnalyst ForecastRYTMRhythm Pharmaceuticals3.7431 of 5 stars$94.31+2.5%$101.57+7.7%+112.9%$6.11B$130.13M-31.33140RNAAvidity Biosciences3.1614 of 5 stars$45.75-1.2%$67.00+46.4%-1.1%$5.96B$10.90M-15.25190Positive NewsOptions VolumeNUVLNuvalent3.1829 of 5 stars$74.95+1.1%$119.60+59.6%+4.8%$5.32BN/A-15.3040News CoverageAnalyst ForecastABVXAbivax3.5268 of 5 stars$69.00-1.6%$92.33+33.8%+545.3%$5.30BN/A0.0061Short Interest ↑AXSMAxsome Therapeutics4.7857 of 5 stars$103.96-0.8%$178.00+71.2%+29.0%$5.23B$385.69M-20.50380Positive NewsCRSPCRISPR Therapeutics3.7972 of 5 stars$55.41+0.7%$71.60+29.2%+20.4%$5.00B$37.31M-10.20460 Related Companies and Tools Related Companies Roivant Sciences Alternatives Grifols Alternatives Legend Biotech Alternatives Revolution Medicines Alternatives Rhythm Pharmaceuticals Alternatives Avidity Biosciences Alternatives Nuvalent Alternatives Abivax Alternatives Axsome Therapeutics Alternatives CRISPR Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IDYA) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEAYA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEAYA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access